Cochrane Review: Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen

Zusammenfassung

# Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. ## BACKGROUND Adjuvant tamoxifen reduces the risk of breast cancer recurrence in women with oestrogen receptor-positive breast cancer. Tamoxifen also increases the risk of postmenopausal bleeding, endometrial polyps, hyperplasia, and endometrial cancer. The levonorgestrel-releasing intrauterine system (LNG-IUS) causes profound endometrial suppression. This systematic review consid

Kerninformationen

en taking adjuvant tamoxifen following breast cancer for the outcomes of endometrial and uterine pathology including abnormal vaginal bleeding or spotting, and secondary breast cancer events. ## SEARCH METHODS We searched the following databases on 29 June 2020; The Cochrane Gynaecology and Fertil...

breast cancer on adjuvant tamoxifen that compared the effectiveness of the LNG-IUS with endometrial surveillance versus endometrial surveillance alone on the incidence of endometrial pathology. ## DATA COLLECTION AND ANALYSIS We used standard methodological procedures recommended by Cochrane. The ...

oderate for all of the outcomes, due to imprecision (i.e. limited sample sizes and low event rates). In the included studies, the active treatment arm was the 20 μg/day LNG-IUS plus endometrial surveillance; the control arm was endometrial surveillance alone. In tamoxifen users, the LNG-IUS probably...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen